The association of toxicities and outcomes with circulating endothelial cells (CEC) in non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (Bev).

被引：0
|
作者：
Sadraei, Nooshin Hashemi
Du, Lingling
Yadav, Ruchi
Grane, Ronald
Jacobs, Barbara
Hamulak, John
Ma, Patrick C.
Pennell, Nathan A.
Elson, Paul
Borden, Ernest C.
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[5] Case Comprehens Canc Ctr, Cleveland, OH USA
[6] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19012
引用
收藏
页数：1
相关论文
共 50 条
  • [21] VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    Carbone, David P.
    Salmon, J. Stuart
    Billheimer, Dean
    Chen, Heidi
    Sandler, Alan
    Roder, Heinrich
    Roder, Joanna
    Tsypin, Maxim
    Herbst, Roy S.
    Tsao, Anne S.
    Tran, Hai T.
    Dang, Thao P.
    LUNG CANCER, 2010, 69 (03) : 337 - 340
  • [22] Radiographic parameters in predicting outcome of patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
    Kaufman, Michael R.
    Salem, Mohamed E.
    Aoun, Hussein
    Kalemkerian, Gregory Peter
    Kunz, Sara
    El-Refai, Sherif
    Ranganath, Praveen
    Sukari, Ammar
    Gadgeel, Shirish M.
    Wozniak, Antoinette J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab
    Boige, V.
    Baey, C.
    Dromain, C.
    Ducreux, M.
    Malka, D.
    Pignon, J.
    Farace, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab
    Boige, Valerie
    Lafoix, Cecile
    Horn, Sarah
    Pignon, Jean-Pierre
    Dromain, Clarisse
    Francoise, Farace
    CANCER RESEARCH, 2009, 69
  • [25] Association between metformin (M) use and survival among non-small cell lung cancer (NSCLC) patients (pts).
    Fortune-Greeley, Alice K.
    Williams, Christina D.
    Paulus, Jessica K.
    Kelley, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Kubota, K.
    Masuhara, H.
    Hosoya, K.
    Yoh, K.
    Niho, S.
    Goto, K.
    Ohmatsu, H.
    Nishiwaki, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
  • [27] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Bernicker, Eric
    Li, Tianhong
    Wang, Victoria
    Ross, Jeffrey S.
    Young, Lauren
    Stephens, Philip J.
    Chung, Jon
    Shaw, Alice Tsang
    Ali, Siraj Mahamed
    Miller, Vincent A.
    Schrock, Alexa Betzig
    Spigel, David R.
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
    Chien, Chun-Ru
    Shih, Ya-Chen Tina
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 201 - 208
  • [29] Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients
    Yuan, Dong-mei
    Zhang, Qin
    Lv, Yan-ling
    Ma, Xing-qun
    Zhang, Yan
    Liu, Hong-bing
    Song, Yong
    TUMOR BIOLOGY, 2015, 36 (11) : 9031 - 9037
  • [30] Role of circulating endothelial cells in the evaluation of response to chemotherapy in non-small cell lung cancer patients
    Al Ammar, M.
    Najjar, F.
    Bashour, M.
    Salmoon, M.
    Almassarani, G.
    Marrawi, Z.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S834 - S834
12345